MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
4.040
-0.040
-0.98%
After Hours: 4.061 +0.021 +0.51% 19:21 04/10 EDT
OPEN
4.080
PREV CLOSE
4.080
HIGH
4.140
LOW
3.930
VOLUME
617.39K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
1.050
MARKET CAP
487.20M
P/E (TTM)
-7.6270
1D
5D
1M
3M
1Y
5Y
1D
Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO
Reuters · 2d ago
Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference
Reuters · 3d ago
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Barchart · 3d ago
Weekly Report: what happened at ACRS last week (0330-0403)?
Weekly Report · 5d ago
Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush
Dow Jones · 03/31 14:11
Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target
Benzinga · 03/31 14:01
Weekly Report: what happened at ACRS last week (0323-0327)?
Weekly Report · 03/30 09:07
Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selective Investigational Oral Covalent Inhibitor Of ITK And JAK3, At 2026 AAD Annual Meeting
Benzinga · 03/27 14:12
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.